



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Tatsuki SHIOTA, et al.

Appln. No. 10/031,698

Group Art Unit: NOT YET ASSIGNED

Confirmation No.: 8252

Examiner: NOT YET ASSIGNED

Filed: January 23, 2002

For: CYCLIC AMINE CCR3 ANTAGONIST

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. § 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Commissioner for Patents
 Box SEQUENCE
 Washington, D.C. 20231

Sir:

Applicant submits the following remarks with respect to the Notification Of Missing Requirements Under 35 U.S.C. § 371 In The United States Designated Office, dated April 2, 2002, in the above-captioned application, for which a response is due by June 3, 2002.

Applicants respectfully assert that no sequence listing is required for the following reason. No compounds are disclosed in the claims or specification having an unbranched sequence of four or more amino acids, and no nucleotide sequences are disclosed. Therefore, the present application does not meet the threshold under 37 C.F.R. § 1.821(a) for a requirement to submit a sequence listing. Accordingly, Applicants request either that the Notification Of Missing Requirements Under 35 U.S.C. § 371 In The United States Designated Office be withdrawn, or the compounds for which a sequence listing is required be specifically identified.

Respectfully submitted,

Christopher J. Kay
 Christopher J. Kay
 Registration No. 44,820

SUGHRUE MION, PLLC
 2100 Pennsylvania Avenue, N.W.
 Washington, D.C. 20037-3213
 Telephone: (202) 293-7060
 Facsimile: (202) 293-7860

Date: May 30, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

2FM

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/031,698	Tatsuki Shiota	Q68142
		INTERNATIONAL APPLICATION NO.
		PCT/JP00/05260
		I.A. FILING DATE PRIORITY DATE
		08/04/2000 08/04/1999
DOCKETED APR 05 2002		
CONFIRMATION NO. 8252 371 FORMALITIES LETTER <small>*OC000000007755090*</small>		

Date Mailed: 04/02/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
- For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/031,698	PCT/JP00/05260	Q68142